Structure Therapeutics

Structure Therapeutics is a biotechnology company whose core business model involves conducting animal testing as part of its drug discovery and development process. The company's pipeline of small-molecule therapeutics, including candidates for obesity and metabolic diseases, requires preclinical testing in animal models to assess efficacy and safety before human trials can begin. This reliance on animal experimentation is standard practice in the pharmaceutical industry but constitutes commercial exploitation of animals under the firm's exclusion policy.

While the company may adhere to institutional animal care and use committee (IACUC) protocols, the fundamental activity remains the use of animals as a research tool. There is no public evidence that Structure Therapeutics is pursuing a wholesale alternative to animal testing or has made a commitment to replace animal models with advanced non-animal methodologies. The exclusion reflects the company's operational dependence on animal testing to advance its product candidates.